How can lymphocytic variant hypereosinophilic syndrome be differentiated from Hodgkin lymphoma presenting with eosinophilia?

Differentiating Lymphocytic Variant HES from Hodgkin Lymphoma with Eosinophilia

The key distinction is that lymphocytic variant HES (L-HES) is driven by clonal aberrant T-cells producing Th2 cytokines (IL-4, IL-5, IL-13) causing reactive eosinophilia, while Hodgkin lymphoma with eosinophilia represents secondary reactive eosinophilia from cytokines produced by Reed-Sternberg cells—the critical differentiator is identifying the specific aberrant T-cell immunophenotype versus finding Reed-Sternberg cells on lymph node biopsy.

Diagnostic Algorithm

Step 1: Tissue Diagnosis

• Perform excisional lymph node biopsy (or adequate core needle biopsy) 1, 2
• Look for Reed-Sternberg cells (CD30+, CD15+ in most cases, CD45-, CD3-) which definitively indicate Hodgkin lymphoma 2
• If Reed-Sternberg cells are present → Hodgkin lymphoma with secondary eosinophilia 1
• If absent, proceed to comprehensive T-cell evaluation for L-HES

Step 2: Flow Cytometry Immunophenotyping (Most Critical Test)

L-HES has a characteristic aberrant T-cell immunophenotype 1:

• Classic phenotype: CD3- (surface), CD4+, CD5+, CD2+, CD45RO+, CD7-/dim, CD8- 3, 4, 5
• This phenotype is highly sensitive and specific with detection limits as low as 0.06% of lymphocytes 4
• Enhanced expression of CD2, CD5, CD45RO, and CD95 allows accurate detection 3
• Variant phenotypes exist: CD3-CD4+ variants, expanded CD3+CD4+CD7- T-cells (>10%), or aberrant CD8+ T-LGL populations 4

Key Point: The aberrant T-cell population in L-HES is double-negative for immature markers (CD3-, CD4-, CD8-) or shows absence of CD3 (CD3-, CD4+) or CD3+, CD4+, CD7- patterns 1

Step 3: Supporting Laboratory Findings

For L-HES 1, 3:

• Elevated serum TARC (CCL17) levels: threshold >3000 pg/mL detects all L-HES cases with 75% specificity 3
• Elevated IgE levels (though neither sensitive nor specific) 1
• Intracytoplasmic cytokine production by flow cytometry showing enhanced IL-4 and IL-13 production is the most reliable method 3

For Hodgkin lymphoma 2:

• B symptoms (fevers >38°C, night sweats, >10% weight loss)
• Elevated ESR, LDH
• PET/CT showing characteristic lymph node involvement patterns

Step 4: Molecular Testing

• TCR gene rearrangement alone is NOT sufficient for L-HES diagnosis 1—it can be nonspecific and found in other HES variants
• TCR clonality detected in 71% of L-HES cases but requires immunophenotypic correlation 5
• For Hodgkin lymphoma: Screen for tyrosine kinase fusion genes (PDGFRA, PDGFRB, FGFR1, JAK2) to exclude myeloid neoplasms 1

Critical Distinguishing Features

L-HES Characteristics:

• Clonal aberrant T-cells with specific immunophenotype drive the process 1
• Eosinophilia is reactive/secondary to Th2 cytokine production 1
• 10-20% risk of evolution to T-cell lymphoma or Sézary syndrome 1
• No Reed-Sternberg cells
• Responds to corticosteroids and anti-IL5 therapy 5

Hodgkin Lymphoma with Eosinophilia:

• Reed-Sternberg cells present on biopsy 2
• Eosinophilia is secondary/reactive to cytokines from neoplastic cells 1
• More frequent in T-cell lymphomas than Hodgkin, but occurs in ~15% of Hodgkin cases 1, 6
• Eosinophilia typically limited to advanced stage disease 1
• Eosinophil counts normalize with lymphoma-directed therapy 7

Common Pitfalls to Avoid

1. Do not rely on TCR gene rearrangement alone—it lacks specificity for L-HES 1
2. Do not assume elevated IgE or TARC is diagnostic—these support but don't confirm L-HES 1
3. Do not skip comprehensive flow cytometry—standard T-cell phenotyping must be adapted to detect the specific aberrant populations 3, 4
4. Do not diagnose L-HES without identifying the aberrant T-cell immunophenotype—this is the cornerstone of diagnosis 3, 4, 5
5. Remember that eosinophilia in both conditions is reactive/secondary, not clonal—the difference lies in what's driving it (aberrant T-cells vs. Reed-Sternberg cells) 1

Clinical Context

The distinction has major prognostic and therapeutic implications 3. Hodgkin lymphoma requires lymphoma-directed chemotherapy/radiotherapy 2, while L-HES requires corticosteroids, anti-IL5 therapy, and monitoring for T-cell lymphoma transformation 1, 5. Excisional lymph node biopsy remains the gold standard first step to identify or exclude Reed-Sternberg cells 2, followed by comprehensive flow cytometry if Hodgkin is excluded 3, 4.